Search - tctmd.com

Displaying 881 - 900 of 1898

Sort: Relevancy | Date

Presentation TCT 2014

Yes: In Select Trials When the Patient Is Stable, Postprocedural Consent Optimizes Understanding and Enrollment!

Presenter: Robert A. Harrington

September 14, 2014

Presentation TCT 2014

Updates and Status of the Cordis Renlane Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Felix Mahfoud

September 14, 2014

Presentation TCT 2014

TCT 135: A Systematic Review and Meta-analysis of Randomized Trials of Manual Thrombectomy in ST Elevation Myocardial Infarction

Presenter: Ashraf Alazzoni, MD

September 14, 2014

Presentation TCT 2014

Updates and Status of the ReCor Paradise Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Thomas Zeller

September 14, 2014

Presentation TCT 2014

Updates and Status of the St. Jude EnligHTN Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

Presentation TCT 2014

Updates and Status of the Boston Scientific Vessix Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Ajay J. Kirtane

September 14, 2014

Presentation TCT 2014

From SYMPLICITY HTN-1 to the Global SYMPLICITY Registry and Beyond: Updates from and Status of the SYMPLICITY Clinical Trial Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Michael Boehm

September 14, 2014

Presentation TCT 2014

Yes: The Data from Numerous Randomized Trials and Large Registries are Clear as a Bell!

Presenter: Fausto Feres

September 14, 2014

Presentation TCT 2014

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, John Flack

September 14, 2014

Presentation TCT 2014

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

Presentation TCT 2014

Relationship Between Infarct Size and Subsequent Mortality Following Primary PCI for STEMI: A Pooled Patient Level Analysis From 10 Trials

Presenter: Steven R. Bailey, Gregg W. Stone

September 14, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

Presentation TCT 2014

DKCRUSH-VI: A Prospective, Randomized Trial of FFR-Guided Versus Angiography-Guided Provisional T-Stenting in Patients with True Coronary Bifurcation Lesions

Presenter: Gregg W. Stone, Pieter C. Smits, Shao Liang Chen

September 14, 2014

Presentation TCT 2014

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

Presenter: Gregg W. Stone, Pieter C. Smits, Patrick W. Serruys

September 14, 2014

News Conference News TCT 2014

TCT Course Director Outlines Current TAVR Controversies

September 14, 2014

News Conference News TCT 2014

Post-PCI STEMI Infarct Size Strong Predictor of Mortality, Rehospitalization

September 14, 2014

News Conference News TCT 2014

Pooled Trial Data Show No Stent Thrombosis Reduction with Biodegradable Stent

September 14, 2014

News Conference News TCT 2014

Lively Debate on Use of TAVR for Lower-Risk Patients

September 14, 2014

News Conference News TCT 2014

LAA Closure Edges Out Medical Therapy for Cost-effectiveness in AF

September 14, 2014

News Conference News TCT 2014

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Yael L. Maxwell

September 14, 2014

Advertisement

Yes: In Select Trials When the Patient Is Stable, Postprocedural Consent Optimizes Understanding and Enrollment!

Updates and Status of the Cordis Renlane Program

TCT 135: A Systematic Review and Meta-analysis of Randomized Trials of Manual Thrombectomy in ST Elevation Myocardial Infarction

Updates and Status of the ReCor Paradise Program

Updates and Status of the St. Jude EnligHTN Program

Updates and Status of the Boston Scientific Vessix Program

From SYMPLICITY HTN-1 to the Global SYMPLICITY Registry and Beyond: Updates from and Status of the SYMPLICITY Clinical Trial Program

Yes: The Data from Numerous Randomized Trials and Large Registries are Clear as a Bell!

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

Relationship Between Infarct Size and Subsequent Mortality Following Primary PCI for STEMI: A Pooled Patient Level Analysis From 10 Trials

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

DKCRUSH-VI: A Prospective, Randomized Trial of FFR-Guided Versus Angiography-Guided Provisional T-Stenting in Patients with True Coronary Bifurcation Lesions

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

TCT Course Director Outlines Current TAVR Controversies

Post-PCI STEMI Infarct Size Strong Predictor of Mortality, Rehospitalization

Pooled Trial Data Show No Stent Thrombosis Reduction with Biodegradable Stent

Lively Debate on Use of TAVR for Lower-Risk Patients

LAA Closure Edges Out Medical Therapy for Cost-effectiveness in AF

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content